They are back at square one. 12 months ago Mundipharma settled the vivagel distribution debacle. Company stated plenty of interest from potential partners, to date other than a Middle East agreement zilch. How does that speak to commercialisation?
Wouldn't you rather see recruitment for the on line platform? Or are they going to pull the plug on Viraleze and Vivagel and return to research? After all the cost of manufacturing v return in sales is a big burden.
Replacement or Expansion, page-4
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
